Drug Database
Back to search

United States· US:0002-7797_60dc1045-5354-4f61-bf71-26129c6b07f4

EBGLYSS

A medicinal product containing lebrikizumab-lbkz, registered in United States by Eli Lilly and Company.

US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedEBGLYSSATC—REGISTER NO.US:0002-7797_60dc1045…PACKS LISTED2CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lebrikizumab-lbkzAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
lebrikizumab-lbkz
Manufacturer
Eli Lilly and Company
Country
United States (US)
ATC code
—
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 12, 2026

Packs & prices · 2

  • ndc11
    0002779711
    1 SYRINGE in 1 CARTON (0002-7797-11) / 2 mL in 1 SYRINGE (0002-7797-01)
  • ndc11
    0002779761
    1 SYRINGE in 1 CARTON (0002-7797-61) / 2 mL in 1 SYRINGE

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lebrikizumab-lbkz in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lebrikizumab-lbkz products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ebglyss
  • Liechtenstein · Ebglyss
  • Norway · Ebglyss

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f4dd192d-6646-40f6-a884-2ac386e52e35
GET /v1/drugs/f4dd192d-6646-40f6-a884-2ac386e52e35?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "SUBCUTANEOUS",
  "livertox": {
    "summary": null,
    "livertox_id": null,
    "hepatotoxicity_score": null
  },
  "productid": "0002-7797_60dc1045-5354-4f61-bf71-26129c6b07f4",
  "productndc": "0002-7797",
  "dosage_form": "INJECTION, SOLUTION",
  "dea_schedule": null,
  "product_type": "HUMAN PRESCRIPTION DRUG",
  "substance_name": "LEBRIKIZUMAB",
  "proprietary_name": "EBGLYSS",
  "active_ingred_unit": "mg/2mL",
  "application_number": "BLA761306",
  "marketing_category": "BLA",
  "nonproprietary_name": "lebrikizumab-lbkz",
  "start_marketing_date": "20240913",
  "active_numerator_strength": "250"
}
API referenceMCP serverPlans

See everything about lebrikizumab-lbkz.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console